Investment Rating - The report suggests a positive outlook for the pharmaceutical sector, indicating that the industry is expected to experience a sustained recovery and structural opportunities remain available [5][41]. Core Insights - The 2025 ASCO conference highlighted a record number of domestic new drug entries, with 74 abstracts accepted, including 34 oral presentations and 32 rapid oral presentations, marking a significant increase from 55 entries in 2024 [7][11]. - Several domestic innovative drugs demonstrated promising clinical data, particularly in oncology, with notable advancements in treatments for advanced non-small cell lung cancer, colorectal cancer, and pancreatic cancer [11][12][15]. - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a rolling P/E ratio of 34.47 compared to 12.56 for the CSI 300, indicating a premium of 174.35% over the index [20][41]. Monthly Policy and Industry Updates - The ASCO 2025 conference showcased a record number of domestic new drugs, with significant clinical data released that attracted market attention [7][11]. - Multiple domestic drugs reported impressive results, particularly in cancer treatment, with specific drugs showing superior efficacy compared to existing therapies [11][12][15]. Industry Data Dynamics - The pharmaceutical sector has shown weaker performance compared to the CSI 300 index, with a decline of 14.00% in the SW pharmaceutical and biological index from early 2023 to June 5, 2025, while the CSI 300 index increased by 0.15% [20]. - The revenue growth of the pharmaceutical manufacturing industry has slowed due to the pandemic's impact, but it continues to grow faster than GDP [23]. - Outpatient expenses have risen due to the pandemic, while inpatient costs have been effectively controlled [26]. Investment Recommendations - The report emphasizes the potential for growth in the pharmaceutical sector, particularly in innovative drugs and their supply chains, as well as in medical devices and third-party medical testing [41][42]. - Specific companies are highlighted for their strong positions in the market, including those involved in innovative drug development and medical device manufacturing [41][42][43].

Core Viewpoint - The recent tightening of U.S. regulatory policies and escalating geopolitical tensions have reignited discussions about the return of Chinese concept stocks (Chinext stocks) to Hong Kong, with the Hong Kong government implementing measures to solidify its position as the preferred destination for these listings [1][7]. Group 1: Market Trends - Since the reform of the listing system in 2018, 33 Chinese concept companies have chosen to list in Hong Kong, accounting for over 70% of the total market capitalization of all Chinese concept stocks [3][4]. - The trend shows that large-cap leading companies are often the first to initiate the return process, with 12 companies having a market capitalization exceeding 1 trillion HKD [4][5]. - As of June 5, 2023, 73% of the top quartile of Chinese concept stocks have achieved a dual listing, with 45% completing a primary dual listing and 26% achieving a secondary listing in Hong Kong [5]. Group 2: Industry Distribution - Chinese concept stocks are primarily concentrated in three sectors: new consumption, technology, and mid-to-high-end manufacturing, with retail accounting for 54% of the new consumption sector [6]. - The valuation discount previously faced by Chinese concept stocks in the Hong Kong market has been gradually alleviated due to increased market activity since last year [6]. Group 3: Government Initiatives - The Hong Kong government is committed to making the region the preferred destination for the return of Chinese concept stocks, with proactive measures being taken by the Securities and Futures Commission and the Hong Kong Stock Exchange [7][8]. - Hong Kong's financial market is characterized by its dual attributes of global capital allocation and local market familiarity, making it an attractive option for Chinese companies looking to return [8]. Group 4: Advantages of Returning to Hong Kong - The flexibility and inclusiveness of Hong Kong's regulatory environment provide significant advantages for Chinese concept stocks, including the ability to retain VIE structures and tax incentives [8]. - Hong Kong serves as a "safe haven," allowing for effective liquidity support from mainland funds while facilitating international capital inflows [7][8].

Group 1 - Hansoh Pharmaceutical granted Regeneron Pharmaceuticals exclusive overseas licensing for its GLP-1/GIP dual receptor agonist HS-20094, which has completed multiple Phase II clinical trials and is currently in Phase III trials in China [1][2] - The licensing agreement includes an upfront payment of $80 million, potential milestone payments of up to $1.93 billion, and double-digit royalties on future sales [2][3] - Recent licensing deals by Chinese pharmaceutical companies indicate a growing trend, with 33 license-out transactions completed in Q1 2025, totaling $36.633 billion, a year-on-year increase of approximately 258% [1][6] Group 2 - The licensing deal with Pfizer for the PD-1/VEGF dual antibody SSGJ-707 includes a record upfront payment of $1.25 billion, with potential milestone payments reaching $4.8 billion [3] - Other companies, such as Sinovant and Ansai, have also announced licensing agreements, indicating a robust market for Chinese pharmaceutical innovations [3][4] - The 2025 ASCO annual meeting showcased over 70 original research results from China, highlighting the international competitiveness of Chinese innovative drugs [4][5] Group 3 - The overall trend shows that Chinese innovative drugs are gaining global value, with a significant increase in licensing transactions and amounts [6][7] - The pharmaceutical industry is expected to see steady recovery, driven by the growing demand for innovative therapies and the improvement in the quality and quantity of domestic innovative drugs [7]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年6月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | 備註： | ...

Group 1 - The pharmaceutical sector has recently experienced a significant pullback, with the innovative drug concept seeing a net outflow of nearly 2.5 billion yuan in A-shares [1] - The Tianhong Innovative Drug ETF (517380) reached a new high for the year before experiencing a substantial decline, dropping 2.75% with a trading volume of 22 million yuan, and most constituent stocks fell nearly 5% [1] - The Tianhong Innovative Drug ETF is the only product tracking the Hang Seng-Hu-Shen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] Group 2 - Dongwu Securities predicts that 2025 will mark the explosive growth of China's innovative drug industry, driven by three core factors: significant BD transactions, profitability turning points for leading companies, and an improving policy environment [2] - Guosheng Securities acknowledges short-term trading pullback risks but emphasizes the solid underlying logic and clear trends in the innovative drug sector, maintaining a positive outlook for the innovative drug bull market [2] - The market size of China's innovative drugs is expected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]

除了电子设备和仪器、集成电路，医疗保健、工业机械、电子元件等板块也获得了较多外资机构的关 注。百济神州、汇川技术、新产业、深南电路等行业龙头接受外资调研的次数位居前列。 ◎记者 王彭 据统计，5月以来，200余家外资机构现身A股上市公司调研名单，累计调研逾500次。具体而言，以电 子设备和仪器、集成电路为代表的硬科技领域是外资关注的焦点。 Wind数据显示，截至6月4日，5月以来共有222家外资机构调研了185家A股公司，累计调研532次。在这 份调研名单上，高盛、富达、贝莱德、瑞银、安联、Point72等机构频频现身。在接受外资机构调研的 行业中，代表硬科技领域的电子设备和仪器、集成电路等板块获得最多外资机构的关注。据统计，奥普 特、澜起科技、沪电股份、奥比中光等公司均吸引了30家以上外资机构的调研。 以澜起科技为例，公司5月29日披露了一份投资者关系活动记录表，瑞银、安联、富达、Point72等知名 外资机构均现身调研名单；沪电股份近日披露的投资者关系活动记录表显示，贝莱德、富达、高盛、摩 根大通等外资机构参与了公司5月19日的特定对象调研。 被称为"华尔街最疯狂的赚钱机器"的Point72在此期间调研1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年5月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二名承授人授出可認 購合共21,140股美國存託股份的購股權並向三百六十八名承授人授出涉及合共 54,538股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2025年5月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二名 承授人可認購合共21,140股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： 授出日期： 2025年5月30日 承授人數目： 二名 授出購股權及受限制股份單位 已授出購股權涉及的相關股份數目： 274,820 購股權總數（美國存託股份）: 21,140 因已授出購股權獲行使而可予 ...

Group 1 - The market experienced a rebound on June 4, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.15 trillion yuan, an increase of 11.6 billion yuan compared to the previous trading day [1] - The innovative drug concept remained active, with the Tianhong Innovative Drug ETF (517380) closing up 2.34%, reaching a peak price of 0.660 yuan, the highest since November 2023, and achieving a trading volume of nearly 20 million yuan, a two-year high [1] - The Tianhong Innovative Drug ETF (517380) has seen a year-to-date increase of 25.96% as of June 4, ranking first among all industry ETFs in the market [1] Group 2 - Changjiang Securities indicated that the valuation level of domestic innovative drugs is low, and some products have the potential to be the best in their class globally, supporting the outlook for innovative drugs to expand internationally and achieve premium valuations [2] - Guojin Securities emphasized that innovative drugs and certain semi-innovative drugs are key investment focuses, with upcoming policy changes and data releases expected to catalyze stock price movements [2] - Huafu Securities reported that the total transaction amount for innovative drug BD from 2020 to 2024 increased from 9.2 billion USD to 52.3 billion USD, with the upfront payment amount rising from 600 million USD to 4.1 billion USD [2]

6月4日，创新药概念继续活跃，相关ETF中，创新药ETF天弘(517380)截至发稿涨2.81%，盘中价格最 高触及0.660元，创2023年11月以来新高。成分股中，信达生物涨超15%，皓元医药、泰格医药、中国 生物制药等涨幅均在6%以上。 消息面上，据新华社消息，2025年1至5月，国家药品监督管理局批准20余款1类创新药上市，数量刷新 近五年同期纪录；2025年美国临床肿瘤学会（ASCO）年会上，70余项中国原创研究成果入选。近来， 国内创新药上市跑出加速度，药企源头创新与国际竞争力同步跃升。业内人士认为，我国创新药领域已 从过去的"跟随式创新"逐步迈向"全球领跑"。中国药企紧紧围绕临床价值核心，在肿瘤靶向、免疫治疗 等关键赛道发力，正悄然改写全球医药格局。 中邮证券认为，创新药板块近期具备较多催化，海外BD、ASCO大会等事件持续提高板块热度。国内 创新药企迎来估值重塑，有望成为贯穿全年的投资主线。下半年国家医保谈判为重要事件，谈判前成功 获批上市创新药有望通过国谈进入医保实现加速放量。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 拉长时间来看， ...

Group 1 - The Chinese innovative pharmaceutical industry is experiencing an unprecedented revaluation, with the innovative drug index rising over 20% and the Hong Kong innovative drug index increasing by more than 45% this year [1][2] - Institutions have shown heightened interest in the innovative drug sector, with numerous companies such as BeiGene and I-Mab being heavily researched by various institutions [1][3] - The focus of institutional research has shifted from generic drugs and raw materials to cutting-edge areas like ADCs, bispecific antibodies, and cell therapies, indicating a growing interest in clinical data and international progress [4][5] Group 2 - The recent surge in the innovative drug sector is attributed to the culmination of years of investment and development, with many projects now reaching commercialization [5][6] - The improvement in liquidity and the influx of foreign capital have significantly boosted the performance of Hong Kong innovative drug stocks, with net purchases exceeding 600 billion yuan this year [6][7] - The next three years are expected to be critical for the Chinese innovative drug industry, with 2025 marking a pivotal year for revenue growth, profitability, and valuation increases [8][9] Group 3 - The innovative drug sector is anticipated to remain a key focus within the pharmaceutical industry, with particular attention on companies that are successfully entering overseas markets and those that are experiencing significant domestic sales growth [9]